Thrombotic Thrombocytopenic Purpura: A Diagnostic and Therapeutic Challenge

ABSTRACT

With the discovery of the ultra-large von Willebrand factor (vWF) in the plasma of thrombotic thrombocytopenic purpura (TTP) patients and the pivotal role played by the ADAMTS13 metalloproteinase, many new challenges are facing both the researcher and the clinician for the diagnosis and treatment of this condition. As a result of these new discoveries, the range of disorders manifesting with many of the clinical features of the disease can now be reclassified into the idiopathic TTP, congenital TTP, and nonidiopathic TTP, based on the level of ADAMTS13 activity. The latter group includes drug-associated TTP. In this article, the background of the pathogenesis, and diagnostic and therapeutic approaches are reviewed. An emerging concept of the pathogenesis of TTP is presented. The merits of various diagnostic procedures including the assay of the ADAMTS13 activity and the immunoglobulin G inhibitory antibodies are discussed. Regarding the therapeutic aspect, although plasma exchange remains the mainstay, the question of addition of immunosuppressive agents comes up, especially in those patients who are refractory to plasma exchange and those that repeatedly relapse. A call for clinical trials to address the question of efficacy of various agents is made.

Thrombotic thrombocytopenic purpura (TTP) - ADAMTS13 - autoantibodies against ADAMTS13 - plasma exchange - immunosuppressive agents

REFERENCES

• 1 Moschcowitz E. Hyaline thrombosis of the terminal arterioles and capillaries: a hitherto undescribed disease.  Proc NY Pathol Soc. 1924;  24 21-24
• 2 Petitt R M. Thrombotic thrombocytopenic purpura: a thirty-year review.  Semin Thromb Hemost. 1980;  6 350-355
• 3 Miller D P, Kaye J A, Shea K et al.. Incidence of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome.  Epidemiology. 2004;  15 208-215
• 4 Terrell D R, Williams L A, Vesely S K et al.. The incidence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: all patients, idiopathic patients and patients with severe ADAMTS-13 deficiency.  J Thromb Haemost. 2005;  3 1432-1436
• 5 Kwaan H C, Soff G A. Management of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome.  Semin Hematol. 1997;  34 159-165
• 6 Moake J L, Rudy C K, Troll J H et al.. Unusually large plasma factor VIII: von Willebrand factor mutations in chronic relapsing thrombotic thrombocytopenic purpura.  N Engl J Med. 1982;  307 1432-1435
• 7 Furlan M, Robles R, Solenthaler M et al.. Deficient activity of von Willebrand factor cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura.  Blood. 1997;  89 3097-3103
• 8 Furlan M, Robles R, Galbusera M et al.. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and hemolytic uremic syndrome.  N Engl J Med. 1998;  339 1578-1584
• 9 Tsai H M, Lian E C. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura.  N Engl J Med. 1998;  339 1585-1594
• 10 Levy G G, Nichols W C, Lian E C et al.. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura.  Nature. 2001;  413 488-494
• 11 Kokame K, Matsumoto M, Soejima K et al.. Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity.  Proc Natl Acad Sci USA. 2002;  99 11902-11907
• 12 Tsai H M. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura.  J Mol Med. 2002;  80 639-647
• 13 Moake J L. Mechanism of disease: thrombotic microangiopathies.  N Engl J Med. 2002;  347 589-600
• 14 Kokame K, Matsumoto M, Soejima K et al.. Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity.  Proc Natl Acad Sci USA. 2002;  99 11902-11907
• 15 Matsumoto M, Kokami K, Soejima K et al.. Molecular characterization of ADAMTS-13 gene mutation in Japanese patients with Upshaw-Schulman syndrome.  Blood. 2003;  103 1305-1310
• 16 Vesely S, George J N, Lämmle B et al.. ADAMTS-13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients.  Blood. 2003;  102 60-68
• 17 Tsai H M. Is severe deficiency of ADAMTS-13 specific for thrombotic thrombocytopenic purpura? Yes.  J Thromb Haemost. 2003;  1 625-631
• 18 Kwaan H C. Miscellaneous secondary thrombotic microangiopathy.  Semin Hematol. 1987;  24 141-147
• 19 Veyradier A, Obert B, Houllier A, Meyer D, Girma J P. Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases.  Blood. 2001;  98 1765-1772
• 20 Peyvandi F, Ferrari S, Lavoretano S, Canciani M T, Mannucci P M. Von Willebrand factor cleaving protease (ADAMTS-13) and ADAMTS-13 neutralizing autoantibodies in 100 patients with thrombotic thrombocytopenic purpura.  Br J Haematol. 2004;  127 433-439
• 21 Zheng X L, Kaufman R M, Goodnough L T, Sadler J E. Effects of plasma exchange on plasma ADAMTS13 metalloproteinase activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura.  Blood. 2004;  103 4043-4049
• 22 Tsai H M, Rice L, Sarode R, Chow T W, Moake J L. Antibody inhibitors to von Willebrand factor metalloproteinase and increased binding of von Willebrand factor to platelets in ticlopidine-associated thrombotic thrombocytopenic purpura.  Ann Intern Med. 2000;  132 794-799
• 23 McCrae K R, Cines D D. Thrombotic microangiopathy during pregnancy.  Semin Hematol. 1997;  34 148-158
• 24 Kwaan H C. Clinicopathologic features of thrombotic thrombocytopenic purpura.  Semin Hematol. 1987;  24 71-81
• 25 Baehr G, Klemperer P, Schlifrin A. An acute febrile anemia and thrombotic purpura with diffuse platelet thrombosis of capillaries and arterioles.  Trans Assoc Am Physicians. 1936;  51 43-58
• 26 Laurence J, Mitra D. Apoptosis of microvascular cells in the pathophysiology of thrombotic thrombocytopenic purpura/sporadic hemolytic uremic syndrome.  Semin Hematol. 1997;  34 98-105
• 27 Mitra D, Jaffe E A, Wensler B et al.. Thrombotic thrombocytopenic purpura and sporadic hemolytic uremic syndrome plasmas induce apoptosis in restricted lineages of human microvascular endothelial cells.  Blood. 1997;  89 1224-1234
• 28 Kim J, Wu H, Hawthorne L, Rafi S, Laurence J. Endothelial cell apoptotic genes associated with the pathogenesis of thrombotic microangiopathies: an application of oligonucleotide genechip technology.  Microvasc Res. 2001;  62 83-93
• 29 Wada H, Kaneko T, Ohiwa M et al.. Increased level of vascular endothelial cell markers in thrombotic thrombocytopenic purpura.  Am J Hematol. 1993;  44 101-105
• 30 Tandon N N, Rock G, Jamieson G A. Anti-CD36 antibodies in thrombotic thrombocytopenic purpura.  Br J Haematol. 1994;  88 816-825
• 31 Jimenez J J, Jy W, Mauro L M, Horstman L L, Ahn Y S. Elevated endothelial microparticles in thrombotic thrombocytopenic purpura: findings from brain and renal microvascular cell culture and patients with active disease.  Br J Haematol. 2001;  112 81-90
• 32 Remuzzi G, Imberti L, DeGaetano G. Prostacyclin deficiency in thrombotic microangiopathy.  Lancet. 1981;  2 1422-1423
• 33 Kwaan H C, Gallo G, Potter E et al.. The nature of the vascular lesion in thrombotic thrombocytopenic purpura.  Ann Intern Med. 1986;  68 1169-1170
• 34 Tsai H M. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura.  J Mol Med. 2002;  80 639-647
• 35 Levy G G, Motto D G, Ginsburg D. ADAMTS13 turns 3.  Blood. 2005;  106 11-17
• 36 Strachan T, Read A P. Human Molecular Genetics 2. New York; John Wiley & Sons 1999: 840-841
• 37 Asada Y, Sumiyoshi A, Hayashi T, Suzumiya J, Kaketani K. Immuno-histocytochemistry of vascular lesion in thrombotic thrombocytopenic purpura with special reference to factor VIII related antigen.  Thromb Res. 1985;  38 469-479
• 38 Sugio Y, Okamura T, Shimoda K et al.. Ticlopidine- associated thrombotic thrombocytopenic purpura with an IgG inhibitor to von Willebrand factor cleaving protease activity.  Int J Haematol. 2001;  74 347-351
• 39 Tsai H M, Schulman K. Rituxan induces remission of cerebral ischemia caused by thrombotic thrombocytopenic purpura.  Eur J Haematol. 2003;  70 183-185
• 40 Zheng X, Pallera A M, Goodnough L T, Sadler J E, Blinder M A. Remission of chronic thrombotic thrombocytopenic purpura after treatment with cyclophosphamide and rituxan.  Ann Intern Med. 2003;  138 105-108
• 41 Allan D S, Kovacs M J, Clark W F. Frequently relapsing thrombotic thrombocytopenic purpura treated with cytotoxic immunosuppressive therapy.  Haematologica. 2001;  86 844-850
• 42 Yomtovian R, Niklinski W, Silver B, Sarode R, Tsai H M. Rituximab for chronic recurring thrombotic thrombocytopenic purpura: a case report and review of the literature.  Br J Haematol. 2004;  124 787-795
• 43 Fakhouri F, Vernant J P, Veyradier A et al.. Efficiency of curative and prophylactic treatment with Rituxan in ADAMTS13 deficient-thrombotic thrombocytopenic purpura: a study of 11 cases.  Blood. 2005;  106 1932-1937
• 44 Emilia G, Morselli M, Luppi M et al.. Long-term salvage therapy with cyclosporin A in refractory idiopathic thrombocytopenic purpura.  Blood. 2002;  69 1482-1485
• 45 Raife T J, Lentz S R, Atkinson B S, Vesely S K, Hessner M J. Factor V Leiden a genetic risk factor for thrombotic microangiopathy in patients with normal von Willebrand factor-cleaving protease activity.  Blood. 2002;  99 437-442
• 46 Wang J, Weiss I, Svoboda K, Kwaan H C. Thrombogenic role of cells undergoing apoptosis.  Br J Haematol. 2001;  115 382-391
• 47 Tripodi A, Chantarangkul V, Bohm M et al.. Measurement of von Willebrand factor cleaving protease (ADAMTS-13): results of an international collaborative study involving 11 methods testing the same set of coded plasmas.  J Thromb Haemost. 2004;  2 1601-1609
• 48 Furlan M, Robles R, Solenthaler M, Lämmle B. Acquired deficiency of von Willebrand factor-cleaving protease in patients with thrombotic thrombocytopenic purpura.  Blood. 1998;  91 2839-2846
• 49 Amar S, Rice L, Dong J-W et al.. Evaluation of ADAMTS-13 von Willebrand factor cleaving protease activity using a rapid endothelial cell surface based assay in two chronic relapsing TTP patients receiving plasma infusion.  Blood. 2002;  100 684a , (abst)
• 50 Gerritsen H E, Turecek P L, Schwarz H P, Lämmle B, Furlan M. Assay of von Willebrand factor (vWF)-cleaving protease based on decreased collagen binding affinity of degraded vWF.  Thromb Haemost. 1999;  82 1386-1389
• 51 Rick M E, Moll S, Taylor M A et al.. Clinical use of a rapid collagen binding assay for von Willebrand factor cleaving protease in patients with thrombotic thrombocytopenic purpura.  Thromb Haemost. 2002;  88 598-604
• 52 Bohm M, Vigh T, Scharrer I. Evaluation and clinical application of a new method for measuring activity of von Willebrand factor-cleaving metalloprotease (ADAMTS13).  Ann Hematol. 2002;  81 430-435
• 53 Kokame K, Nobe Y, Kokubo Y, Kayana A, Miyata T. FRETS-VWF72, a first fluorogenic substrate for ADAMTS13 assay.  Br J Haematol. 2005;  129 93-100
• 54 Scheiflinger F, Knobl P, Trattner B et al.. Nonneutralizing IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura.  Blood. 2003;  102 3241-3243
• 55 Klaus C, Plaimauer B, Studt J-D et al.. Epitope mapping of ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura.  Blood. 2004;  103 4514-4519
• 56 Zheng X, Nishio K, Majerus E M, Sadler J E. Cleavage of von Willebrand factor requires the spacer domain of the metalloprotease ADAMTS13.  J Biol Chem. 2003;  278 30136-30141
• 57 Ai J, Smith P, Wang S, Zhang P, Zheng X L. The proximal carboxyl terminal domains of ADAMTS13 determine substrate specificity and are all required for cleavage of von Willebrand factor.  J Biol Chem. 2005;  280 29428-29434
• 58 Praprotnik S, Blank M, Levy Y et al.. Anti-endothelial cell antibodies from patients with thrombotic thrombocytopenic purpura specifically activate small vessel endothelial cells.  Int J Immunol. 2001;  13 203-210
• 59 Studt J-D, Hovinga J A, Radonic R et al.. Familial acquired thrombotic thrombocytopenic purpura: ADAMTS13 inhibitory autoantibodies in identical twins.  Blood. 2004;  103 4195-4197
• 60 Hymes K B, Karpatian S. Human immunodeficiency virus infection and thrombotic microangiopathy.  Semin Hematol. 1997;  34 117-125
• 61 Novitzky N, Thomson J, Abrahams L, du Toit C, McDonald A. Thrombotic thrombocytopenic purpura in patients with retroviral infection is highly responsive to plasma infusion therapy.  Br J Haematol. 2005;  128 373-379
• 62 Sahud M A, Claster S, Liu L et al.. Von Willebrand factor-cleaving protease inhibitor in a patient with human immunodeficiency syndrome-associated thrombotic thrombocytopenic purpura.  Br J Haematol. 2002;  116 909-911
• 63 Gruszecki A C, Wehrli G, Ragland B D et al.. Management of a patient with HIV infection-induced anemia and thrombocytopenia who presented with thrombotic thrombocytopenic purpura.  Am J Hematol. 2002;  69 228-231
• 64 Fessler B J. Thrombotic syndromes and autoimmune diseases.  Rheum Dis Clin North Am. 1997;  23 461-479
• 65 Pistiner M, Wallace D J, Nessim S, Metzger A L, Klinenberg J R. Lupus erythematosus in the 1980s: a survey of 570 patients.  Semin Arthritis Rheum. 1991;  21 55-64
• 66 Porta C, Bobbio-Pallavicini E, Centurioni R, Caporali R, Montecucco C M. Thrombotic thrombocytopenic purpura in systemic lupus erythematosus. Italian Cooperative Group for TTP.  J Rheumatol. 1993;  20 1625-1626
• 67 Bobbio-Pallavicini E, Gugliotta L, Centurioni R et al.. Antiplatelet agents in thrombotic thrombocytopenic purpura (TTP). Results of a randomized multicenter trial by the Italian Cooperative Group for TTP.  Haematologica. 1997;  82 429-435
• 68 Porta C, Caporali R, Montecucco C. Thrombotic thrombocytopenic purpura and autoimmunity: a tale of shadows and suspects.  Haematologica. 1999;  84 260-269
• 69 Bernardo A, Ball C, Nolasco L, Moake J F, Dong J F. Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow.  Blood. 2004;  104 100-106
• 70 Wada H, Kaneko T, Ohiwa M et al.. Plasma cytokine levels in thrombotic thrombocytopenic purpura.  Am J Hematol. 1992;  40 167-170
• 71 Motto D, Zheng W, Zhu G et al.. Additional environmental and/or genetic factors are required to trigger TTP in ADAMTS13 deficient mice.  Blood. 2004;  104 77a , (abst)
• 72 Rubinstein M A, Kagan B M, MacGilliviray M H, Merliss R, Sacks H. Unusual remission in a case of thrombotic thrombocytopenic purpura syndrome following fresh blood exchange transfusions.  Ann Intern Med. 1959;  51 1409-1419
• 73 Rizvi M A, Vesely S K, George J N et al.. Complications of plasma exchange in 71 consecutive patients treated for clinically suspected thrombotic thrombocytopenic purpura/hemolytic uremic syndrome.  Transfusion. 2000;  40 896-901
• 74 Moake J L, Byrnes J J, Troll J H et al.. Effects of fresh frozen plasma and its cryosupernatant fraction on von Willebrand factor multimeric forms in chronic relapsing thrombotic thrombocytopenic purpura.  Blood. 1985;  65 1232-1236
• 75 Byrnes J J, Moake J L, Klug P et al.. Effectiveness of the cryosupernatant fraction of plasma in the treatment of refractory thrombotic thrombocytopenic purpura.  Am J Hematol. 1990;  34 169-174
• 76 Obrador G T, Zeigler Z R, Shadduck R K et al.. Effectiveness of the cryosupernatant therapy in refractory and chronic relapsing thrombotic thrombocytopenic purpura.  Am J Hematol. 1993;  42 217-220
• 77 Rock G, Shumak K H, Sutton D M et al.. Cryosupernatant as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura. Members of the Canadian Apheresis Group.  Br J Haematol. 1996;  94 383-386
• 78 Zeigler Z R, Shadduck R K, Gryn J F et al.. Cryoprecipitate poor plasma does not improve early response in adult thrombotic thrombocytopenic purpura (TTP).  J Apheresis. 2001;  16 19-22
• 79 Bandarenko N, Brecher M E. United States Thrombotic Thrombocytopenic Purpura Apheresis Study Group (US TTP ASG): multicenter survey and retrospective analysis of current efficiency of therapeutic plasma exchange.  J Clin Apheresis. 1998;  13 133-141
• 80 Jobin F, Delage J M. Aspirin and prednisone in microangioapthic haemolytic anaemia.  Lancet. 1970;  2 208-210
• 81 Rosove M H, Ho W G, Goldfinger D. Ineffectiveness of aspirin and dipyridamole in the treatment of thrombotic thrombocytopenic purpura.  Ann Intern Med. 1982;  96 27-33
• 82 Amorosi E L, Karpatkin S. Antiplatelet therapy of thrombotic thrombocytopenic purpura.  Ann Intern Med. 1977;  86 102-106
• 83 Eckel R H, Crowell E B, Waterhouse B E, Bozdech M J. Platelet-inhibiting drugs in thrombotic thrombocytopenic purpura.  Arch Intern Med. 1977;  137 735-737
• 84 Budd G T, Bukowski R M, Lucas F V, Cato A E, Cocchetto D M. Prostacyclin therapy of thrombotic thrombocytopenic purpura.  Lancet. 1980;  2 915
• 85 Ishii Y, Ebata H, Satoh K et al.. Case of thrombotic thrombocytopenic purpura. Successful treatment with ticlopidine.  Jpn J Clin Hematol. 1984;  25 1097-1102
• 86 Bukowski R M, Hewlett J S, Reimer R R et al.. Therapy of thrombotic thrombocytopenic purpura: an overview.  Semin Thromb Hemost. 1981;  7 1-8
• 87 Gordon L I, Kwaan H C, Rossi E C. Deleterious effects of platelet transfusions and recovery thrombocytosis in patients with thrombotic microangiopathy.  Semin Hematol. 1987;  24 194-201
• 88 Kwaan H C, Domer P H. Fatal thrombotic thrombocytopenic purpura despite plasmapheresis. A case report of autopsy findings.  Haemostasis. 1989;  19 344-347
• 89 Finn N G, Wang J C, Hong K J. High-dose intravenous gamma-immunoglobulin infusion in the treatment of thrombotic thrombocytopenic purpura.  Arch Intern Med. 1987;  147 2165-2167
• 90 Kolodziej M. Case report: high-dose intravenous immunoglobulin as therapy for thrombotic thrombocytopenic purpura.  Am J Med Sci. 1993;  305 101-102
• 91 Kwaan H C. A rational, unified approach to the problem of thrombotic thrombocytopenic purpura.  Semin Thromb Hemost. 1979;  5 241-242
• 92 Kwaan H C. Thrombotic thrombocytopenic purpura.  JAMA. 1982;  247 3119-3120